Search

Your search keyword '"Barthelemy, O."' showing total 133 results
Start Over Author "Barthelemy, O."
133 results on '"Barthelemy, O."'

1. Phenotyping Coronary Plaque by Computed Tomography in Premature Coronary Artery Disease

Author

Rahoual, G., primary, Zeitouni, M., additional, Charpentier, E., additional, Ritvo, P.-G., additional, Rouanet, S., additional, Procopi, N., additional, Boukhelifa, S., additional, Charleux, P., additional, Guedeney, P., additional, Kerneis, M., additional, Barthelemy, O., additional, Silvain, J., additional, Montalescot, G., additional, Redheuil, A., additional, and Collet, J.-P., additional

Published
2024
Full Text
View/download PDF

2. Incidence and determinants of non-radial vascular approach for coronary angiography among heart transplant recipients

Author

Procopi, N, primary, Guedeney, P, additional, Zeitouni, M, additional, Kerneis, M, additional, Barthelemy, O, additional, Le Feuvre, C, additional, Silvain, J, additional, Berman, E, additional, Coutance, G, additional, Varnous, S, additional, Leprince, P, additional, Lebreton, G, additional, Collet, J P, additional, Montalescot, G, additional, and Helft, G, additional

Published
2023
Full Text
View/download PDF

6. Comparison of the safety and efficacy of antithrombotic regimens following TAVR in patients without having an indication for chronic oral anticoagulation

Author

Guedeney, P, primary, Roule, V, additional, Mesnier, J, additional, Chapelle, C, additional, Portal, J J, additional, Laporte, S, additional, Ollier, E, additional, Zeitouni, M, additional, Kerneis, M, additional, Barthelemy, O, additional, Sorrentino, S, additional, Silvain, J, additional, Vicaut, E, additional, Montalescot, G, additional, and Collet, J P, additional

Published
2022
Full Text
View/download PDF

8. Combinatorial, additive and dose-dependent drug-microbiome associations

Author

Forslund, SK, Chakaroun, R, Zimmermann-Kogadeeva, M, Markó, L, Aron-Wisnewsky, J, Nielsen, T, Moitinho-Silva, L, Schmidt, TSB, Falony, G, Vieira-Silva, S, Adriouch, S, Alves, RJ, Assmann, K, Bastard, J-P, Birkner, T, Caesar, R, Chilloux, J, Coelho, LP, Fezeu, L, Galleron, N, Helft, G, Isnard, R, Ji, B, Kuhn, M, Le Chatelier, E, Myridakis, A, Olsson, L, Pons, N, Prifti, E, Quinquis, B, Roume, H, Salem, J-E, Sokolovska, N, Tremaroli, V, Valles-Colomer, M, Lewinter, C, Søndertoft, NB, Pedersen, HK, Hansen, TH, Amouyal, C, Andersson Galijatovic, EA, Andreelli, F, Barthelemy, O, Batisse, J-P, Belda, E, Berland, M, Bittar, R, Blottière, H, Bosquet, F, Boubrit, R, Bourron, O, Camus, M, Cassuto, D, Ciangura, C, Collet, J-P, Dao, M-C, Djebbar, M, Doré, A, Engelbrechtsen, L, Fellahi, S, Fromentin, S, Galan, P, Gauguier, D, Giral, P, Hartemann, A, Hartmann, B, Holst, JJ, Hornbak, M, Hoyles, L, Hulot, J-S, Jaqueminet, S, Jørgensen, NR, Julienne, H, Justesen, J, Kammer, J, Krarup, N, Kerneis, M, Khemis, J, Kozlowski, R, Lejard, V, Levenez, F, Lucas-Martini, L, Massey, R, Martinez-Gili, L, Maziers, N, Medina-Stamminger, J, Montalescot, G, Moute, S, Neves, AL, Olanipekun, M, Le Pavin, LP, Poitou, C, Pousset, F, Pouzoulet, L, Rodriguez-Martinez, A, Rouault, C, Silvain, J, Svendstrup, M, Swartz, T, Vanduyvenboden, T, Vatier, C, Walther, S, Gøtze, JP, Køber, L, Vestergaard, H, Hansen, T, Zucker, J-D, Hercberg, S, Oppert, J-M, Letunic, I, Nielsen, J, Bäckhed, F, Ehrlich, SD, Dumas, M-E, Raes, J, Pedersen, O, Clément, K, Stumvoll, M, Bork, P, The MetaCardis Consortium (Hoyles, L.), European Molecular Biology Laboratory [Heidelberg] (EMBL), Max Delbrück Center for Molecular Medicine [Berlin] (MDC), Helmholtz-Gemeinschaft = Helmholtz Association, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), German Center for Cardiovascular Research (DZHK), Universität Leipzig, Nutrition et obésités: approches systémiques (UMR-S 1269) (Nutriomics), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Copenhagen = Københavns Universitet (UCPH), University of New South Wales [Sydney] (UNSW), Paul Scherrer Institute (PSI), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Heidelberg University, Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Université Sorbonne Paris Nord-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Henri Mondor [Créteil], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], University of Gothenburg (GU), Imperial College London, MetaGenoPolis (MGP (US 1367)), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Paris-Saclay, Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Chalmers University of Technology [Gothenburg, Sweden], Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] (UMMISCO), Université de Yaoundé I-Institut de la francophonie pour l'informatique-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Université Gaston Bergé (Saint-Louis, Sénégal)-Université Cadi Ayyad [Marrakech] (UCA)-Sorbonne Université (SU)-Institut de Recherche pour le Développement (IRD [France-Nord]), Centre d'investigation clinique Paris Est [CHU Pitié Salpêtrière] (CIC Paris-Est), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Biobyte Solutions [Heidelberg, Germany] (BS), IT University of Copenhagen (ITU), Sahlgrenska University Hospital [Gothenburg], Metabolic functional (epi)genomics and molecular mechanisms involved in type 2 diabetes and related diseases - UMR 8199 - UMR 1283 (EGENODIA (GI3M)), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, McGill University and Genome Quebec Innovation Centre, Helmholtz Institute Ulm (HIU), Helmholtz Zentrum München = German Research Center for Environmental Health, University of Würzburg = Universität Würzburg, Yonsei University, MetaCardis Consortium*: Chloe Amouyal, Ehm Astrid Andersson Galijatovic, Fabrizio Andreelli, Olivier Barthelemy, Jean-Paul Batisse, Eugeni Belda, Magalie Berland, Randa Bittar, Hervé Blottière, Frederic Bosquet, Rachid Boubrit, Olivier Bourron, Mickael Camus, Dominique Cassuto, Cecile Ciangura, Jean-Philippe Collet, Maria-Carlota Dao, Morad Djebbar, Angélique Doré, Line Engelbrechtsen, Soraya Fellahi, Sebastien Fromentin, Pilar Galan, Dominique Gauguier, Philippe Giral, Agnes Hartemann, Bolette Hartmann, Jens Juul Holst, Malene Hornbak, Lesley Hoyles, Jean-Sebastien Hulot, Sophie Jaqueminet, Niklas Rye Jørgensen, Hanna Julienne, Johanne Justesen, Judith Kammer, Nikolaj Krarup, Mathieu Kerneis, Jean Khemis, Ruby Kozlowski, Véronique Lejard, Florence Levenez, Lea Lucas-Martini, Robin Massey, Laura Martinez-Gili, Nicolas Maziers, Jonathan Medina-Stamminger, Gilles Montalescot, Sandrine Moute, Ana Luisa Neves, Michael Olanipekun, Laetitia Pasero Le Pavin, Christine Poitou, Francoise Pousset, Laurence Pouzoulet, Andrea Rodriguez-Martinez, Christine Rouault, Johanne Silvain, Mathilde Svendstrup, Timothy Swartz, Thierry Vanduyvenboden, Camille Vatier, Stefanie Walther., ANR-16-IDEX-0004,ULNE,ULNE(2016), ANR-18-IBHU-0001,PreciDIAB,PreciDIAB Institute, the holistic approach of personal diabets care(2018), Dumas, Marc-Emmanuel, Universität Leipzig [Leipzig], Service de Nutrition [CHU Pitié-Salpétrière], Institut E3M [CHU Pitié-Salpêtrière], CHU Henri Mondor, Centre d'investigation clinique pluridisciplinaire [CHU Pitié Salpêtrière] (CIC-1901(ex CIC-1421)), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Imperial College London - National Heart and Lung Institute, and Division of Computational and Systems Medicine, Imperial College London, London, SW7 2AZ, UK

Subjects
Clostridiales, Science & Technology, Multidisciplinary, ANTIBIOTIC USE, IMPACT, Microbiota, [SDV]Life Sciences [q-bio], HUMAN GUT MICROBIOME, Atherosclerosis, Gastrointestinal Microbiome, [SDV] Life Sciences [q-bio], Multidisciplinary Sciences, PROTON PUMP INHIBITORS, Cardiovascular and Metabolic Diseases, GUIDELINE, Metabolome, MANAGEMENT, Humans, Science & Technology - Other Topics, ALTERS
Abstract

During the transition from a healthy state to cardiometabolic disease, patients become heavily medicated, which leads to an increasingly aberrant gut microbiome and serum metabolome, and complicates biomarker discovery1-5. Here, through integrated multi-omics analyses of 2,173 European residents from the MetaCardis cohort, we show that the explanatory power of drugs for the variability in both host and gut microbiome features exceeds that of disease. We quantify inferred effects of single medications, their combinations as well as additive effects, and show that the latter shift the metabolome and microbiome towards a healthier state, exemplified in synergistic reduction in serum atherogenic lipoproteins by statins combined with aspirin, or enrichment of intestinal Roseburia by diuretic agents combined with beta-blockers. Several antibiotics exhibit a quantitative relationship between the number of courses prescribed and progression towards a microbiome state that is associated with the severity of cardiometabolic disease. We also report a relationship between cardiometabolic drug dosage, improvement in clinical markers and microbiome composition, supporting direct drug effects. Taken together, our computational framework and resulting resources enable the disentanglement of the effects of drugs and disease on host and microbiome features in multimedicated individuals. Furthermore, the robust signatures identified using our framework provide new hypotheses for drug-host-microbiome interactions in cardiometabolic disease. ispartof: NATURE vol:600 issue:7889 pages:500-+ ispartof: location:England status: published

Published
2021

11. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Author

Collet, J. -P., Thiele, H., Barbato, E., Bauersachs, J., Dendale, P., Edvardsen, T., Gale, C. P., Jobs, A., Lambrinou, E., Mehilli, J., Merkely, B., Roffi, M., Sibbing, D., Kastrati, A., Mamas, M. A., Aboyans, V., Angiolillo, D. J., Bueno, H., Bugiardini, R., Byrne, R. A., Castelletti, S., Chieffo, A., Cornelissen, V., Crea, Filippo, Delgado, V., Drexel, H., Gierlotka, M., Halvorsen, S., Haugaa, K. H., Jankowska, E. A., Katus, H. A., Kinnaird, T., Kluin, J., Kunadian, V., Landmesser, U., Leclercq, C., Lettino, M., Meinila, L., Mylotte, D., Ndrepepa, G., Omerovic, E., Pedretti, R. F. E., Petersen, S. E., Petronio, A. S., Pontone, G., Popescu, B. A., Potpara, T., Ray, K. K., Luciano, F., Richter, D. J., Shlyakhto, E., Simpson, I. A., Sousa-Uva, M., Storey, R. F., Touyz, R. M., Valgimigli, M., Vranckx, P., Yeh, R. W., Barthelemy, O., Bhatt, D. L., Dorobantu, M., Folliguet, T., Gilard, M., Juni, P., Lewis, B. S., Meliga, E., Mueller, C., Rutten, F. H., Siontis, G. C. M., Crea F. (ORCID:0000-0001-9404-8846), Collet, J. -P., Thiele, H., Barbato, E., Bauersachs, J., Dendale, P., Edvardsen, T., Gale, C. P., Jobs, A., Lambrinou, E., Mehilli, J., Merkely, B., Roffi, M., Sibbing, D., Kastrati, A., Mamas, M. A., Aboyans, V., Angiolillo, D. J., Bueno, H., Bugiardini, R., Byrne, R. A., Castelletti, S., Chieffo, A., Cornelissen, V., Crea, Filippo, Delgado, V., Drexel, H., Gierlotka, M., Halvorsen, S., Haugaa, K. H., Jankowska, E. A., Katus, H. A., Kinnaird, T., Kluin, J., Kunadian, V., Landmesser, U., Leclercq, C., Lettino, M., Meinila, L., Mylotte, D., Ndrepepa, G., Omerovic, E., Pedretti, R. F. E., Petersen, S. E., Petronio, A. S., Pontone, G., Popescu, B. A., Potpara, T., Ray, K. K., Luciano, F., Richter, D. J., Shlyakhto, E., Simpson, I. A., Sousa-Uva, M., Storey, R. F., Touyz, R. M., Valgimigli, M., Vranckx, P., Yeh, R. W., Barthelemy, O., Bhatt, D. L., Dorobantu, M., Folliguet, T., Gilard, M., Juni, P., Lewis, B. S., Meliga, E., Mueller, C., Rutten, F. H., Siontis, G. C. M., and Crea F. (ORCID:0000-0001-9404-8846)

Abstract

N/A

Published
2021

14. One-Year Outcomes after PCI Strategies in Cardiogenic Shock

Author

Thiele, H, Akin, I, Sandri, M, de Waha-Thiele, S, Meyer-Saraei, R, Fuernau, G, Eitel, I, Nordbeck, P, Geisler, T, Landmesser, U, Skurk, C, Fach, A, Jobs, A, Lapp, H, Piek, JJ, Noc, M, Goslar, T, Felix, SB, Maier, LS, Stepinska, J, Oldroyd, K, Serpytis, P, Montalescot, G, Barthelemy, O, Huber, K, Windecker, S, Hunziker, L, Savonitto, S, Torremante, P, Vrints, C, Schneider, S, Zeymer, U, Desch, S, Investigators, CULPRIT-SHOCK, Mamas, MA, Cardiology, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and CULPRIT-SHOCK Investigators

Subjects
medicine.medical_specialty, medicine.medical_treatment, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Infarction, 610 Medicine & health, 030204 cardiovascular system & hematology, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, 030212 general & internal medicine, Myocardial infarction, cardiovascular diseases, business.industry, Cardiogenic shock, R735, Percutaneous coronary intervention, General Medicine, RC666, medicine.disease, R1, Heart failure, Conventional PCI, Cardiology, Myocardial infarction complications, Human medicine, business, RA, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Item does not contain fulltext BACKGROUND: Among patients with acute myocardial infarction, cardiogenic shock, and multivessel coronary artery disease, the risk of a composite of death from any cause or severe renal failure leading to renal-replacement therapy at 30 days was found to be lower with percutaneous coronary intervention (PCI) of the culprit lesion only than with immediate multivessel PCI. We evaluated clinical outcomes at 1 year. METHODS: We randomly assigned 706 patients to either culprit-lesion-only PCI or immediate multivessel PCI. The results for the primary end point of death or renal-replacement therapy at 30 days have been reported previously. Prespecified secondary end points at 1 year included death from any cause, recurrent myocardial infarction, repeat revascularization, rehospitalization for congestive heart failure, the composite of death or recurrent infarction, and the composite of death, recurrent infarction, or rehospitalization for heart failure. RESULTS: As reported previously, at 30 days, the primary end point had occurred in 45.9% of the patients in the culprit-lesion-only PCI group and in 55.4% in the multivessel PCI group (P=0.01). At 1 year, death had occurred in 172 of 344 patients (50.0%) in the culprit-lesion-only PCI group and in 194 of 341 patients (56.9%) in the multivessel PCI group (relative risk, 0.88; 95% confidence interval [CI], 0.76 to 1.01). The rate of recurrent infarction was 1.7% with culprit-lesion-only PCI and 2.1% with multivessel PCI (relative risk, 0.85; 95% CI, 0.29 to 2.50), and the rate of a composite of death or recurrent infarction was 50.9% and 58.4%, respectively (relative risk, 0.87; 95% CI, 0.76 to 1.00). Repeat revascularization occurred more frequently with culprit-lesion-only PCI than with multivessel PCI (in 32.3% of the patients vs. 9.4%; relative risk, 3.44; 95% CI, 2.39 to 4.95), as did rehospitalization for heart failure (5.2% vs. 1.2%; relative risk, 4.46; 95% CI, 1.53 to 13.04). CONCLUSIONS: Among patients with acute myocardial infarction and cardiogenic shock, the risk of death or renal-replacement therapy at 30 days was lower with culprit-lesion-only PCI than with immediate multivessel PCI, and mortality did not differ significantly between the two groups at 1 year of follow-up. (Funded by the European Union Seventh Framework Program and others; CULPRIT-SHOCK ClinicalTrials.gov number, NCT01927549 .).

Published
2018

23. P961Investigator versus Core Lab evaluation of coronary blood flow in PCI of patients in cardiogenic shock: a substudy of the CULPRIT-SHOCK trial

Author

Zeitouni, M, primary, Barthelemy, O, additional, Rouanet, S, additional, Guedeney, P, additional, Hauguel-Moreau, M, additional, Hage, G, additional, Overtchouk, P, additional, Brugier, D, additional, Vignolles, N, additional, Kerneis, M, additional, Silvain, J, additional, Collet, J P, additional, Vicaut, E, additional, Thiele, H, additional, and Montalescot, G, additional

Published
2019
Full Text
View/download PDF

24. P3855Incidence, risk factors and impact of readmission for heart failure after successful transcatheter aortic valve replacement

Author

Guedeney, P, primary, Huchet, F, additional, Manigold, F, additional, Rouanet, S, additional, Vicaut, E, additional, Balagny, P, additional, Leprince, P, additional, Lebreton, G, additional, Letocart, V, additional, Barthelemy, O, additional, Montalescot, G, additional, Guerin, P, additional, and Collet, J P, additional

Published
2019
Full Text
View/download PDF

26. P3124Predictive value of the residual SYNTAX score following primary PCI in multivessel patients with MI-related cardiogenic shock - a CULPRIT SHOCK sub-analysis

Author

Barthelemy, O, primary, Rouanet, S, additional, Brugier, D, additional, Vignoles, N, additional, Bertin, B, additional, Zeitouni, M, additional, Guedeney, P, additional, Overtchouk, P, additional, Hage, G, additional, Hauguel-Moreau, M, additional, Akin, I, additional, Desch, S, additional, Vicaut, E, additional, Thiele, H, additional, and Montalescot, G, additional

Published
2019
Full Text
View/download PDF

27. 1155Prognostic impact of SYNTAX Score in patients with myocardial infarction with multivessel coronary artery disease and cardiogenic shock: insight from the CULPRIT-SHOCK Trial

Author

Guedeney, P, primary, Barthelemy, O, additional, Zeitouni, M, additional, Hauguel-Moreau, M, additional, Hage, G, additional, Overtchouk, P, additional, Rouanet, S, additional, Vicaut, E, additional, De Waha-Thiele, S, additional, Zeymer, U, additional, Sandri, M, additional, Akin, I, additional, Desch, S, additional, Thiele, H, additional, and Montalescot, G, additional

Published
2019
Full Text
View/download PDF

30. Incidence, risk factors and impact of readmission for heart failure after successful transcatheter aortic valve replacement

Author

Guedeney, P., primary, Huchet, François, additional, Manigold, T., additional, Rouanet, S., additional, Vicaut, E., additional, Balagny, P., additional, Leprince, P., additional, Lebreton, G., additional, Letocart, V., additional, Barthelemy, O., additional, Montalescot, G., additional, Guérin, Patrice, additional, and Collet, J.P., additional

Published
2019
Full Text
View/download PDF

32. One-Year Outcomes after PCI Strategies in Cardiogenic Shock

Author

Thiele, H., Akin, I., Sandri, M., Waha-Thiele, S. de, Meyer-Saraei, R., Fuernau, G., Eitel, I., Nordbeck, P., Geisler, T., Landmesser, U., Skurk, C., Fach, A., Jobs, A., Lapp, H., Piek, J.J., Noc, M., Goslar, T., Felix, S.B., Maier, L.S., Stepinska, J., Oldroyd, K., Serpytis, P., Montalescot, G., Barthelemy, O., Huber, K., Windecker, S., Hunziker, L., Savonitto, S., Torremante, P., Vrints, C., Schneider, S., Geuns, R.J.M. van, Zeymer, U., Desch, S., Thiele, H., Akin, I., Sandri, M., Waha-Thiele, S. de, Meyer-Saraei, R., Fuernau, G., Eitel, I., Nordbeck, P., Geisler, T., Landmesser, U., Skurk, C., Fach, A., Jobs, A., Lapp, H., Piek, J.J., Noc, M., Goslar, T., Felix, S.B., Maier, L.S., Stepinska, J., Oldroyd, K., Serpytis, P., Montalescot, G., Barthelemy, O., Huber, K., Windecker, S., Hunziker, L., Savonitto, S., Torremante, P., Vrints, C., Schneider, S., Geuns, R.J.M. van, Zeymer, U., and Desch, S.

Abstract

Item does not contain fulltext, BACKGROUND: Among patients with acute myocardial infarction, cardiogenic shock, and multivessel coronary artery disease, the risk of a composite of death from any cause or severe renal failure leading to renal-replacement therapy at 30 days was found to be lower with percutaneous coronary intervention (PCI) of the culprit lesion only than with immediate multivessel PCI. We evaluated clinical outcomes at 1 year. METHODS: We randomly assigned 706 patients to either culprit-lesion-only PCI or immediate multivessel PCI. The results for the primary end point of death or renal-replacement therapy at 30 days have been reported previously. Prespecified secondary end points at 1 year included death from any cause, recurrent myocardial infarction, repeat revascularization, rehospitalization for congestive heart failure, the composite of death or recurrent infarction, and the composite of death, recurrent infarction, or rehospitalization for heart failure. RESULTS: As reported previously, at 30 days, the primary end point had occurred in 45.9% of the patients in the culprit-lesion-only PCI group and in 55.4% in the multivessel PCI group (P=0.01). At 1 year, death had occurred in 172 of 344 patients (50.0%) in the culprit-lesion-only PCI group and in 194 of 341 patients (56.9%) in the multivessel PCI group (relative risk, 0.88; 95% confidence interval [CI], 0.76 to 1.01). The rate of recurrent infarction was 1.7% with culprit-lesion-only PCI and 2.1% with multivessel PCI (relative risk, 0.85; 95% CI, 0.29 to 2.50), and the rate of a composite of death or recurrent infarction was 50.9% and 58.4%, respectively (relative risk, 0.87; 95% CI, 0.76 to 1.00). Repeat revascularization occurred more frequently with culprit-lesion-only PCI than with multivessel PCI (in 32.3% of the patients vs. 9.4%; relative risk, 3.44; 95% CI, 2.39 to 4.95), as did rehospitalization for heart failure (5.2% vs. 1.2%; relative risk, 4.46; 95% CI, 1.53 to 13.04). CONCLUSIONS: Among patients with acute myo

Published
2018

36. 1213Post-TAVR antithrombotic treatment and one-year survival: insights from the FRANCE TAVI registry

Author

Overtchouk, P, primary, Guedeney, P, additional, Montalescot, G, additional, Verhoye, J P, additional, Koning, R, additional, Lefevre, T L, additional, Van Belle, E, additional, Eltchaninoff, H, additional, Gilard, M, additional, Leprince, P, additional, Iung, B, additional, Barthelemy, O, additional, Silvain, J, additional, Le Breton, H, additional, and Collet, J P, additional

Published
2018
Full Text
View/download PDF

37. A prospective cardiometabolism ApPRoach of mechanisms of coronary plaque rupture to apprehend patients at risk of recurrent events — The APPROACH registry

Author

Lattuca, B., primary, Kerneis, M., additional, Lesnik, P., additional, Guerin, M., additional, Legoff, W., additional, Leroy, T., additional, Barthelemy, O., additional, Helft, G., additional, Lefeuvre, C., additional, Brugier, D., additional, Collet, J.P., additional, Montalescot, G., additional, and Silvain, J., additional

Published
2018
Full Text
View/download PDF

39. 2050Impact on clinical outcome of on-treatment platelet reactivity according to concordant platelet function tests: the multi-test platelet function study

Author

Guedeney, P., primary, Pellaton, C., additional, Hulot, J.S., additional, Kerneis, M., additional, Silvain, J., additional, Barthelemy, O., additional, Brugier, D., additional, Eekhout, E., additional, Diallo, A., additional, Vicaut, E., additional, Montalescot, G., additional, and Collet, J.P., additional

Published
2017
Full Text
View/download PDF

41. P2771What is the current need for PCI and extra-corporal-life-support (ECLS) in patients referred to a tertiary center for out-of-hospital-cardiac-arrest?

Author

Benais, M., primary, Silvain, J., additional, Brechot, N., additional, Guedeney, P., additional, Kerneis, M., additional, Luyt, C.E., additional, Barthelemy, O., additional, Hekimian, G., additional, Hauguel-Moreau, M., additional, Helft, G., additional, Le Feuvre, C., additional, Collet, J.P., additional, Combes, A., additional, and Montalescot, G., additional

Published
2017
Full Text
View/download PDF

42. Impact of screening by coronary angiography and revascularization by angioplasty of significant coronary lesions before transcatheter aortic valve implantation

Author

El Hatimi, S., primary, Hammoudi, N., additional, Barthelemy, O., additional, Choussat, R., additional, Collet, J.P., additional, Berthelot, E., additional, Bouchachi, A., additional, Assayag, P., additional, Leprince, P., additional, Lefeuvre, C., additional, and Helft, G., additional

Published
2017
Full Text
View/download PDF

43. Real life versus score-predicted mortality in patients presented to the Heart Team

Author

Cacoub, L., primary, Kerneis, M., additional, Silvain, J., additional, Hammoudi, N., additional, Barthelemy, O., additional, Pousset, F., additional, Isnard, R., additional, Thomas, D., additional, Collet, J.P., additional, Hidden-Lucet, F., additional, Laali, M., additional, Barreda, T., additional, Pavie, A., additional, Leprince, P., additional, and Montalescot, G., additional

Published
2017
Full Text
View/download PDF

44. Determinants of high platelet reactivity in rapid metabolizers with acute coronary syndrome

Author

Collet, J. P., Kerneis, M., Cvetinović, Nataša, Lončar, Goran, Silvain, J., Brugier, D., Barthelemy, O., Vignalou, J. B., Payot, L., Radojičić, Zoran, Mansencal, N., Montalescot, G., Collet, J. P., Kerneis, M., Cvetinović, Nataša, Lončar, Goran, Silvain, J., Brugier, D., Barthelemy, O., Vignalou, J. B., Payot, L., Radojičić, Zoran, Mansencal, N., and Montalescot, G.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results